¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"HIV Long Terminal Repeat"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • terminal nerve corpuscle
    Á¾¸»½Å°æ¼Òü
  • terminal deflection
    Á¾¸»ÆíÇâ
  • terminal device
    ¸»´ÜÀåÄ¡
  • encapsulated nerve terminal
    ÇǸ·½Å°æ¼Òü
  • free nerve terminal
    ÀÚÀ¯½Å°æÁ¾¸»
  • terminal filament
    ³¡¹Ì¼¼¼¶À¯
  • terminal foot
    Á¾¸»¹ß
  • terminal ganglion
    Á¾¸»½Å°æÀý
  • terminal groove
    ºÐ°è°í¶û
  • terminal hair
    Á¾¸»ÅÐ
  • terminal ileitis
    ¸»´Üµ¹Ã¢ÀÚ¿°, ¸»´ÜȸÀå¿°
  • terminal infection
    ¸»±â°¨¿°
  • terminal latency
    Á¾¸»Àá½Ã
  • terminal line
    ºÐ°è¼±
  • nerve terminal
    ½Å°æÁ¾¸»
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • long calcaneocuboid ligament ; ligament plantare longum
    Àåô Àδë.
  • long capillary loop
    ±ä¸ð¼¼Ç÷°ü°í¸®
  • long central artery
    ±äÁ߽ɵ¿¸Æ
  • long ciliary nerve
    ±ä¼¶¸ðü½Å°æ
  • long ciliary nerves
    ±ä¼¶¸ðü½Å°æ, Àå¸ð¾çü½Å°æ(íþÙ¾åÆô÷ãêÌè
  • long ciliary nerves
    ±ä¼¶¸ðü½Å°æ, Àå¸ð¾çü½Å°æ(íþÙ¾åÆô÷ãêÌè).
  • long crus
    ±ä´Ù¸®
  • long day plants
    ÀåÀϽŰ(íþìíãÕÚª).
  • long distance irradiation
    Àå°Å¸®Ä¡·á
  • long extensor muscle of great toe ³ª muscle extensor hallucis longus
    Àå ¹«Áö ½Å±Ù.
  • long extensor muscle of thumb ³ª muscle extensor pollicis longus
    Àå ¸ðÁö ½Å±Ù.
  • long extensor muscle of toes ³ª muscle extensor digitorum longus
    Àå Áö ½Å±Ù.
  • long flexor muscle of great toe ³ª muscle flexor hallucis longus
    Àå ¹«Áö±¼±Ù.
  • long flexor muscle of thumb ³ª muscle flexor pollicis longus
    Àå ¸ðÁö ±¼±Ù.
  • long flexor muscle of toes ³ª muscle flexor digitorum longus
    Àå Áö±¼ ±Ù.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Terminal ventricle
    Á¾¸»³ú½Ç
    [¿¾ ¿ë¾î] Á¾½Ç
  • Terminal bulb
    Á¾¸»¸Á¿ï
    [¿¾ ¿ë¾î] Á¾¸»±¸
  • Terminal capillary
    Á¾¸»¸ð¼¼Ç÷°ü
    [¿¾ ¿ë¾î] Á¾¸»¸ð¼¼Ç÷°ü
  • Terminal foot
    Á¾¸»¹ß
    [¿¾ ¿ë¾î] Á¾¸»Á·
  • Terminal portion
    Á¾¸»ºÎºÐ
    [¿¾ ¿ë¾î] Á¾¸»ºÎ
  • Terminal portion
    Á¾¸»ºÎÀ§
    [¿¾ ¿ë¾î] Á¾¸»ºÎ
  • Terminal portion
    Á¾¸»ºÎÀ§
    [¿¾ ¿ë¾î] Á¾¸»ºÐºñºÎ
  • Terminal bronchiole
    Á¾¸»¼¼±â°üÁö
    [¿¾ ¿ë¾î] Á¾¸»¼¼±â°üÁö
  • Terminal cistern
    Á¾¸»¼öÁ¶
    [¿¾ ¿ë¾î] Á¾¸»¼ÒÁ¶
  • Terminal calyx
    Á¾¸»¼úÀÜ
    [¿¾ ¿ë¾î] Á¾¸»¹è
  • Terminal nerve
    Á¾¸»½Å°æ
    [¿¾ ¿ë¾î] Á¾½Å°æ
  • Terminal corpuscle
    Á¾¸»½Å°æ¼Òü
    [¿¾ ¿ë¾î] ½Å°æÁ¾¸»¼Òü
  • Terminal ganglion
    Á¾¸»½Å°æÀý
    [¿¾ ¿ë¾î] Á¾½Å°æÀý
  • Terminal glial cell
    Á¾¸»¾Æ±³¼¼Æ÷
    [¿¾ ¿ë¾î] Á¾¸»±³¼¼Æ÷
  • Terminal villi
    Á¾¸»À¶¸ð
    [¿¾ ¿ë¾î] Á¾¸»À¶¸ð
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • terminal transferase
    ¸»´Ü(ØÇÓ®) Æ®·£½ºÆÛ·¹À̽º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CD8 HIV suppressor cell count
HIV human immunodeficiency virus
HIV Ag human immunodeficiency virus antigen
HIV-G human immunodeficiency virus-associated gingivitis
IWB indeterminate [HIV-1] Western blot; index of well being
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HIV-1 PR HIV-1 protease
MOS-HIV Medical Outcome Study HIV Health Survey
ITR inverted terminal repeat
TIR terminal inverted repeat
TR terminal repeat
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • spinothalamic terminal
    ô¼ö ½Ã»ó Á¾¸»
  • terminal axon
    ¸»´Ü Ãà»è
  • terminal bones
    Æó¼âÁ¦, Á¢ÇÕÁ¦
    »óÇÇ ¼¼Æ÷ÀÇ À¯¸® ¸éÀ» ¼­·Î Á¢Âø½ÃŰ´Â °áÇÕ ±¸Á¶ ȤÀº Á¢Âø´ë.
  • terminal bronchiol
    Á¾¸» ¼¼±â°üÁö, ¸»´Ü ¼¼°üÁö
  • terminal closing clicking joint noise
    Æó±¸ ¸»±âÀÇ ´Ü¼ø °üÀý ÀâÀ½
  • terminal field
    ¸»´ÜºÎ
  • terminal hinge axis
    Á¾¸» Á¢¹øÃà
    µ¿ÀǾî=transverse horizontal axis.
  • terminal hinge position
    Á¾¸» Á¢¹øÀ§
    ±³ÇÕÀÇ °í°æ°ú Áß½ÉÀ§¿¡¼­ Çü¼ºµÇ´Â ÇϾÇÀÇ »ó¾Ç¿¡ ´ëÇÑ °ü°è ±â·ÏÀÌ´Ù.
  • terminal ileum
    ȸÀå ¸»´ÜºÎ
  • terminal occlusion
    ÃÖÁ¾ ±³ÇÕ
    Æò¸éÀû Á¢ÃË ¶Ç´Â ±³ÇÕÀÌ ÃÖ´ëÇÑÀ¸·Î µÇ´Â ´ëÇÕÄ¡ÀÇ ±³Çո鰣 °ü°è.
  • terminal pattern
    ¸»´Ü ÇüÅÂ
  • terminal plane
    ¿ø½É¸é, Á¾¸»»ó, ÈÄ¹æ Æò¸é
  • terminal stage
    ¸»±â
  • terminal uerve corpuscle
    ½Å°æ Á¾¸» ¼Òü, Á¾¸»Ã¼, Á¾¸» ½Å°æÃ¼
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
HIV envelope protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120,000 kD and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably t4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
(12 Dec 1998)
HIV envelope protein gp160 An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kD and contains numerous glycosylation sites. It serves as a precursor for both the HIV envelope protein gp120 and the HIV envelope protein gp41.
(12 Dec 1998)
HIV envelope protein gp41 Transmembrane envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The n-terminal part of gp41 is thought to be involved in cell fusion with the CD4 antigens of t4 lymphocytes, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by immunoblotting.
(12 Dec 1998)
HIV infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru aids-related complex (arc), to acquired immunodeficiency syndrome (aids).
(12 Dec 1998)
HIV integrase <enzyme> Enzyme of the human immunodeficiency virus that is required to integrate viral DNA into cellular DNA in the nucleus of a host cell. HIV integrase is a DNA nucleotidyltransferase encoded by the pol gene.
Registry number: EC 2.7.7.-
(12 Dec 1998)
HIV integrase inhibitors Inhibitors of HIV integrase, an enzyme required for integration of viral DNA into cellular DNA.
(12 Dec 1998)
HIV protease <enzyme> Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene.
Registry number: EC 3.4.23.-
(12 Dec 1998)
HIV protease inhibitors Inhibitors of HIV protease, an enzyme required for production of proteins needed for viral assembly.
(12 Dec 1998)
HIV seronegativity Immune status consisting of non-production of HIV antibodies, as determined by various serological tests.
(12 Dec 1998)
HIV seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/lav).
(12 Dec 1998)
HIV seroprevalence Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV seropositivity).
(12 Dec 1998)
HIV test <investigation> A test which is performed on a standard venipuncture blood specimen which detects the presence of antibodies to HIV (virus). This test may not be positive for 3 to 6 months after infection with HIV.
(27 Sep 1997)
HIV wasting syndrome <syndrome> Involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhoea or fatigue for more than 30 days in the absence of a defined cause other than HIV infection. A constant feature is major muscle wasting with scattered myofibre degeneration. A variety of aetiologies, which vary among patients, contributes to this syndrome.
(12 Dec 1998)
absolute terminal innervation ratio The number of motor endplates divided by the number of terminal axons related to them.
(05 Mar 2000)
amino-terminal <biochemistry> The end of a protein or polypeptide chain with the unattached amino group or the aminoacyl residue containing it.
Each amino acid in the chain has an amino group on one side, which is attached to the carboxyl group (COOH group) of the previous amino acid, and a carboxyl group on the other side (which is attached to the amino group of the next amino acid). The other end of the polypeptide chain is called the carboxyl terminal.
Synonym: NH2-terminal.
(14 Aug 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • long
    ±ä;±æ´Ù¶õ;¿À·¡ °É¸®´Â;Áö·çÇÑ;ÀåÀ½ÀÇ;°­¼¼ÀÇ;´Ù·®ÀÇ;a ~ way off ¸Õ (from);draw a ~ face ħ¿ï(Â·è)ÇÑ ¾ó±¼À» ÇÏ´Ù
  • long
    ±æ°Ô;¿À·§µ¿¾È;ÀüºÎÅÍ;...ÁÙ°ð;all day ~ Á¾ÀÏ;any ~er ¹ú½á;ÀÌ ÀÌ»ó;at (the) ~est ±æ¾î¾ß;±â²¯Çؾß;no ~er ÀÌ¹Ì ... ¾Æ´Ï´Ù;...À̸é
  • long
    ¿À·§µ¿¾È;Çϱâ ÈÞ°¡;Àå¸ðÀ½;before(ere)~ ¸ÓÁö ¾Ê¾Æ;for ~ ¿À·§µ¿¾È;The ~ and the short of it is that ... °£´ÜÈ÷ ¸»ÇÏÀÚ¸é;°á±¹Àº
  • long
    °£ÀýÈ÷ ¹Ù¶ó´Ù;»ç¸ðÇÏ´Ù
  • long clothes
    ¹è³»¿Ê;±âÀú±Í
  • long date
    Àå±âÀÇ »óȯ ±âÀÏ
  • long distance
    Àå°Å¸® ÀüÈ­;Àå°Å¸® ±³È¯±¹(¼ö)
  • long division
    ÀåÁ¦¹ý(12)ÀÌ»óÀÇ ¼ö·Î ³ª´©´Â ³ª´°¼À
  • long dozen
    13°³(baker's dozen)
  • long drawn
    ±æ°Ô »«(´ÃÀÎ);±æ´Ù¶õ
  • long drink
    ź»ê¼ö µîÀ» ź ¼ú (ÇÏÀ̺¼ µî)
  • long ears
    ¹àÀº±Í;³ª±Í°°Àº;¿ìµÐÇÑ
  • long face
    ½Ã¹«·è(ħÅë)ÇÑ ¾ó±¼
  • long family
    ´ë°¡Á·
  • long field
    (Å©¸®ÄÏ)¿Ü¾ß(long off ³ª long on)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á